Immunic, Inc.

NASDAQ: IMUX · Healthcare · Biotechnology

PublicHQ New York City, NY · New YorkCIK 0001280776Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 28DQ —GM —SS 62

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ return on assets, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$97.2M

Employees

as of 2026-08-14

Market cap

$225.8M

as of 2026-08-14

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$97.2M-$97.2M2025

Operating income-$103.2M-$103.2M2025

Total assets$24.1M$24.1M2025

Liabilities$30.7M$30.7M2025

Equity-$6.7M-$6.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Immunic, Inc.’s financial profile?

Immunic, Inc. earned -$97.2M in FY2025 net income.

Peers · Healthcare

Alamar Biosciences, Inc.——Aurora Cannabis Inc.——Greenwich LifeSciences, Inc.——AN2 Therapeutics, Inc.——Galectin Therapeutics Inc.——PepGen Inc.——

Neighbors

New York →

JPMorgan Chase & Co.$182.4B72B Morgan Stanley$34.3B61C The Goldman Sachs Group, Inc.——Philip Morris International Inc.$40.6B86A American Express Company$41.3B78B+Citigroup Inc.$85.2B55C

Key facts

CEOErik Lundgren

SectorHealthcare

IndustryBiotechnology

HeadquartersNew York City, NY

ExchangeNASDAQ: IMUX

Employees95

IPO date2014-04-17

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-07-14 8-K2026-07-06 8-K2026-06-29 DEF 14A2026-05-29 8-K2026-05-28 8-K2026-05-27

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.